Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 6/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MDM4 | O15151 | 1/20 | 0.36 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.36 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL65066 | 0.86 | HSP90AA1 (0.50) | MEN1KMT2APOLBALDH1A1TSHR | |
| Hydrochloric Acid SCHEMBL9061399 | 0.85 | HSP90AA1 (0.49) | MEN1KMT2APOLBALDH1A1TSHR | |
| Bromide SCHEMBL6879691 | 0.85 | HSP90AA1 (0.49) | MEN1KMT2APOLBALDH1A1TSHR | |
| SCHEMBL25419697 | 0.83 | HSP90AA1 (0.40) | MEN1KMT2APOLBPTGS2ALDH1A1 | |
| SCHEMBL23351367 | 0.77 | MEN1 (0.49) | MEN1KMT2APOLBALDH1A1TSHR | |
| SCHEMBL7933455 | 0.75 | MEN1 (0.47) | MEN1KMT2APOLBALDH1A1TSHR | |
| SCHEMBL15859624 | 0.74 | MEN1 (0.46) | MEN1KMT2APOLBPTGS2ALDH1A1 | |
| SCHEMBL2392064 | 0.74 | LMNA (0.50) | MEN1KMT2APOLBALDH1A1TSHR | |
| SCHEMBL13883829 | 0.74 | MEN1 (0.46) | MEN1KMT2APOLBALDH1A1TSHR | |
| SCHEMBL852873 | 0.72 | TSHR (0.50) | MEN1KMT2AALDH1A1TSHRHSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140309174-A1 | HEMIASTERLIN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF CANCER | EISAI CO., LTD (JP) | 2014-10-16 | — | — | US | disclosed |
| US-8633224-B2 | Hemiasterlin derivatives and uses thereof in the treatment of cancer | EISAI CO., LTD. (JP) | 2014-01-21 | — | — | US | disclosed |
| US-20120309938-A1 | HEMIASTERLIN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF CANCER | EISAI CO., LTD. (JP) | 2012-12-06 | — | — | US | disclosed |
| US-8129407-B2 | Hemiasterlin derivatives and uses thereof in the treatment of cancer | EISAI INC. (US) | 2012-03-06 | — | — | US | disclosed |
| EP-2374454-A1 | Hemiasterlin derivatives and uses thereof in the treatment of cancer | Eisai R&D Management Co., Ltd. (JP) | 2011-10-12 | — | — | EP | disclosed |
| US-20100063095-A1 | HEMIASTERLIN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF CANCER | EISAI CO., LTD. (JP) | 2010-03-11 | — | — | US | disclosed |
| US-7585976-B2 | Hemiasterlin derivatives and uses thereof | EISAI CO., LTD. (JP) | 2009-09-08 | — | — | US | disclosed |
| US-7528152-B2 | synthetic analog of Hemiasterlin; anticarcinogenic agent; restenosis of blood vessels subject to traumas such as angioplasty and stenting; safe and effective, while retaining stability in biological media; exhibit low cytotoxicity to non-dividing normal cells | EISAI CO., LTD. (JP) | 2009-05-05 | — | — | US | disclosed |
| US-20080108820-A1 | Hemiasterlin Derivatives and Uses Thereof | EISAI CO., LTD. (JP) | 2008-05-08 | — | — | US | disclosed |
| US-20080051434-A1 | synthetic analog of Hemiasterlin; anticarcinogenic agent; restenosis of blood vessels subject to traumas such as angioplasty and stenting; safe and effective, while retaining stability in biological media; exhibit low cytotoxicity to non-dividing normal cells | EISAI CO., LTD. (JP) | 2008-02-28 | — | — | US | disclosed |
| US-7192972-B2 | Hemiasterlin derivatives and uses thereof | EISAI CO., LTD. (JP) | 2007-03-20 | — | — | US | disclosed |
| US-20060154872-A1 | Hemiasterlin derivatives and uses thereof | EISAI CO., LTD. (JP) | 2006-07-13 | — | — | US | disclosed |
| US-7064211-B2 | Hemiasterlin derivatives and uses thereof | EISAI CO., LTD. (JP) | 2006-06-20 | — | — | US | disclosed |
| EP-1664088-A2 | HEMIASTERLIN DERIVATIVES AND USES THEREOF | Eisai Co. Ltd. (JP) | 2006-06-07 | — | — | EP | disclosed |
| US-20050239870-A1 | Prevention of restenosis of blood vessels after trauma, angioplasty or stenting; aminoalkylamide, piperidine-, indole-, or pyrrole-amide derivatives; anticarcinogenic agents | Eisai Co., Ltd., (JP) | 2005-10-27 | — | — | US | disclosed |
| WO-2005030794-A2 | HEMIASTERLIN DERIVATIVES AND USES THEREOF | EISAI CO. LTD. (JP) | 2005-04-07 | — | — | WO | disclosed |
| EP-1490054-A2 | HEMIASTERLIN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF CANCER | Eisai Co., Ltd (JP) | 2004-12-29 | — | — | EP | disclosed |
| US-20040229819-A1 | Hemiasterlin derivatives and uses thereof | EISAI CO., LTD. (JP) | 2004-11-18 | — | — | US | disclosed |
| WO-2003082268-A2 | HEMIASTERLIN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF CANCER | EISAI CO. LTD (JP) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060154872-A1 | Hemiasterlin derivatives and uses thereof | DHCR7, HSD17B7, HCCS | MEN1 274/4885KMT2A 3297/4885POLB 3558/4885 |
| US-20100063095-A1 | HEMIASTERLIN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF CANCER | DHCR7, HSD17B7, HCCS | MEN1 251/4885KMT2A 3692/4885POLB 3602/4885 |
| US-20080108820-A1 | Hemiasterlin Derivatives and Uses Thereof | DHCR7, HSD17B7, HCCS | MEN1 274/4885KMT2A 3297/4885POLB 3558/4885 |
| US-20050239870-A1 | Prevention of restenosis of blood vessels after trauma, angioplasty or stenting; aminoalkylamide, piperidine-, indole-, or pyrrole-amide derivatives; anticarcinogenic agents | EDNRA, ARG1, EDNRB | MEN1 3741/4885KMT2A 2295/4885POLB 1106/4885 |
| US-20120309938-A1 | HEMIASTERLIN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF CANCER | DHCR7, HSD17B7, HCCS | MEN1 251/4885KMT2A 3692/4885POLB 3602/4885 |
| US-20140309174-A1 | HEMIASTERLIN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF CANCER | DHCR7, HSD17B7, HCCS | MEN1 251/4885KMT2A 3692/4885POLB 3602/4885 |
| US-20040229819-A1 | Hemiasterlin derivatives and uses thereof | HSD17B7, CYP17A1, DHCR7 | MEN1 257/4885KMT2A 2835/4885POLB 3037/4885 |
| US-20080051434-A1 | synthetic analog of Hemiasterlin; anticarcinogenic agent; restenosis of blood vessels subject to traumas such as angioplasty and stenting; safe and effective, while retaining stability in biological media; exhibit low cytotoxicity to non-dividing normal cells | DHCR7, CYP46A1, NR1H2 | MEN1 173/4885KMT2A 3889/4885POLB 2884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.